Optimization of hammerhead ribozymes for the cleavage of S100A4 (CAPL) mRNA

Antisense and Nucleic Acid Drug Development

Volumn 11, Issue 2, 2001, Pages 67-75

  Hovig, E ^a   Maelandsmo G ^a   Mellingsaeter T ^a   Fodstad, O ^a   Mielewczyk, S S ^b,c   Wolfe, J ^b,d   Goodchild, J ^b,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HYBRIDON INC   (United States)

^c US Genomics Inc   (United States)

^d Variagenics Inc   (United States)

^e UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALVASCULIN; MESSENGER RNA; NUCLEASE; RIBOZYME; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; DNA FLANKING REGION; METASTASIS INHIBITION; OSTEOSARCOMA CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; RNA CLEAVAGE;

EID: 0035029010     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729001750171272     Document Type: Article

References (43)

1. Enzymatic cleavage of RNA by RNA (Nobel Lecture)
2. Chemical modification of hammerhead ribozymes - Catalytic activity and nuclease resistance
3. The structure, function and application of the hammerhead ribozyme
4. Biological catalysis by RNA
5. Facilitator oligonucleotides increase ribozyme RNA binding to full-length RNA substrates in vitro
6. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonucleoase in plasma
7. Kinetics of intermolecular cleavage by hammerhead ribozymes
8. Improved free-energy parameters for predictions of RNA duplex stability
9. Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2′-O-methylation
10. Optimization of hammerhead flanking sequences using oligonucleotide facilitators
11. Ribozymes that cleave an RNA sequence from human immunodeficiency virus: The effect of flanking sequence on rate
12. Ribozyme-mediated inhibition of expression of leukocyte-type 12-lipoxygenase in porcine aortic vascular smooth muscle cells
13. Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1
14. Unexpected anisotrophy in substrate cleavage rates by asymmetric hammerhead ribozymes
15. Specificity of hammerhead ribozyme cleavage
16. Thermodynamic dissection of the substrate-ribozyme interaction in the hammerhead ribozyme
17. The subcellular localization and length of hammerhead ribozymes determines efficacy in human cells
18. Efficient improvement of hammerhead ribozyme mediated cleavage of long substrates by oligonucleotide facilitators
19. Peptide nucleic acid (PNA) is capable of enhancing hammerhead ribozyme activity with long but not with short RNA substrates
20. Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA
21. Sequence specificity of the hammerhead ribozyme revisited: The NHH rule
22. Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
23. Further studies on the use of oligonucleotide facilitators to increase ribozyme turnover
24. Nuclease resistant ribozymes with high catalytic activity
25. Fluorescence resonance energy transfer analysis of ribozyme kinetics reveals the mode of action of a facilitator oligonucleotide
26. Extended target-site specificity for a hammerhead ribozyme
27. Intracellular metabolism of a 2′-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or as free ribozyme. A study by capillary electrophoresis
28. Thiophosphate interference experiments locate phosphates important for the hammerhead RNA self-cleavage reaction
29. Generality of the NUX rule: Kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes
30. Structural variation induced by different nucleotides at the cleavage site of the hammerhead ribozyme
31. Labile exocyclic amine protection of nucleosides in DNA, RNA and oligonucleotide analog synthesis facilitating N-deacylation, minimizing depurination and chain degradation
32. Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-a production by peritoneal cells in vitro and in vivo
33. Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates
34. Hybridization prediction gets to first base
35. Small catalytic RNAs
36. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: Advantages of an asymmetric design
37. Tetranucleotide GGGA motif in primary RNA transcripts - Novel target site for antisense design
38. Catalytic RNA (ribozymes) as drugs
39. Automated chemical synthesis of long oligoribonucleotides using 2′-O-silylated ribonucleoside 3′-O-phosphoramidites on a controlled-pore glass support: Synthesis of a 43-nucleotide sequence similar to the 3′-half molecule of an Escherichia coli formylmethionine tRNA
40. Minimum ribonucleotide requirement for catalysis by the RNA hammerhead domain
41. Cleavage of highly structured viral RNA molecules by combinatorial libraries of hairpin ribozymes - The most effective ribozymes are not predicted by substrate selection rules
42. Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes